卢马视觉将其4D成像平台扩展到两个欧洲医院进行心房动试验,推动美国的批准和未来的心脏手术应用. LUMA Vision expands its 4D imaging platform to two European hospitals for atrial fibrillation trials, advancing U.S. approval and future heart procedure applications.

卢马视觉已将其VERAFEYETM 4D成像平台扩展到布拉格和斯普利特的两个欧洲医院,用于对心房动消去进行临床试验. 该项目使用实时360度图像来指导脉冲场消去和其他技术的程序. LUMA Vision has expanded its VERAFEYE™ 4D imaging platform to two European hospitals in Prague and Split for clinical trials on atrial fibrillation ablation, using real-time 360-degree imaging to guide procedures with pulsed field ablation and other technologies. 该公司完成了该系统的510k) 提交,这是2026年在美国商业推出这一关键步骤. The company completed a 510(k) submission for the system, a key step toward its 2026 commercial launch in the U.S. 该平台可实现单操作员,精确的导管导航,并得到欧洲和爱尔兰资金支持, 计划将其应用扩展到心脏结构干预如门放置和左耳前庭附属物关闭. The platform enables single-operator, precise catheter navigation and is backed by European and Irish funding, with plans to extend its use to structural heart interventions like valve placement and left atrial appendage closure.